0001193125-11-194814.txt : 20110722 0001193125-11-194814.hdr.sgml : 20110722 20110722163139 ACCESSION NUMBER: 0001193125-11-194814 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20110720 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20110722 DATE AS OF CHANGE: 20110722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chelsea Therapeutics International, Ltd. CENTRAL INDEX KEY: 0001333763 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 203174202 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51462 FILM NUMBER: 11982865 BUSINESS ADDRESS: STREET 1: 3530 TORINGDON WAY STREET 2: SUITE 200 CITY: CHARLOTTE STATE: NC ZIP: 28277 BUSINESS PHONE: 704-341-1516 MAIL ADDRESS: STREET 1: 3530 TORINGDON WAY STREET 2: SUITE 200 CITY: CHARLOTTE STATE: NC ZIP: 28277 8-K 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 20, 2011

 

 

CHELSEA THERAPEUTICS

INTERNATIONAL, LTD.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-51462   20-3174202

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

ID Number)

3530 Toringdon Way, Suite 200, Charlotte, North Carolina   28277
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (704) 341-1516

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01. Other Events.

On July 20, 2011, Chelsea Therapeutics International, Ltd. issued a press release announcing that it will release second quarter 2011 results after the market closes on Tuesday, July 26, 2011. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

 

  (d) Exhibits

 

Exhibit
No.

   

Description

99.1    Press release dated July 20, 2011.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CHELSEA THERAPEUTICS INTERNATIONAL, LTD.

Date: July 22, 2011

  

/s/ J. Nick Riehle

  J. Nick Riehle, Chief Financial Officer

 

3

EX-99.1 2 dex991.htm PRESS RELEASE Press release

Exhibit 99.1

 

LOGO    Press Release

 

 

Chelsea Therapeutics to Host Conference Call to Discuss Second Quarter 2011 Results

Charlotte, NC, July 20, 2011 – Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) announced that it will release second quarter results for the period ended June 30, 2011 after the market closes on Tuesday, July 26, 2011. Chelsea management will host a conference call and live webcast to discuss these financial results and provide an update on each of its development programs that afternoon at 4:30 PM ET.

Interested investors may participate in the conference call by dialing 877-638-9567 (domestic) or 720-545-0009 (international). A replay will be available for one week following the call by dialing 855-859-2056 for domestic participants or 404-537-3406 for international participants and entering passcode 84867259 when prompted. Participants may also access both the live and archived webcast of the conference call on Chelsea’s web site at www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea’s most advanced drug candidate, NORTHERA™ (droxidopa), is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).

This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include our need to raise operating capital, our history of losses, risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates Droxidopa and CH-4051, reliance on collaborations and licenses, intellectual property risks, competition, market acceptance for our products if any are approved for marketing and reliance on key personnel including specifically Dr. Pedder.

***

 

Investors:    Media:
Kathryn McNeil    Lauren Tortorete
Chelsea Therapeutics    Hill & Knowlton
704-973-4231    212-885-0348
mcneil@chelseatherapeutics.com    lauren.tortorete@hillandknowlton.com
 GRAPHIC 3 g214347ex991pg001.jpg GRAPHIC begin 644 g214347ex991pg001.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`'P"U`P$1``(1`0,1`?_$`*,```("`@(#`0`````` M``````8'``@%"0,*`0($"P$``00#`0$!````````````!@`$!0<"`PD!"`H0 M```'``$#`P(#!08'``````$"`P0%!@<(`!$2(1,4(A4Q%A5?_`"V3_P#7V?\`9?HLX'_]QAO_`&M3_?CZ[,$3"RUCFFD% M!1[F5EY1W\5A'M">XX=+G$P@0@")2@`%*)C&,(%*4!$1``$>N,JD",$^F@Z_ M1))_4;\S_GU;S'=LOO'23?Y3/.^559O$DW[-[' M2)&X'#\2@<1,4_J8O6#HL@W@]($CL>DEM>VS^W6!E,RK)M$1D4U4:0<*T5.Y M(R29P(0H%(4I2^@B.:($&@Z\)UZP>-?[O9?\`S]5/ MXRTZR?\`0WY=)?7K?KU'];>J=ZWOFH'U]#CKQQI53M>FLJ>QT#0;AI$O*Q.: M9;5)F0>Q5;++H5YLYL5HM5H>1KDS.,:&;=FSS:E15:389"(XHH@R[Y7W>Y@JH3U4'+.>/V`[WJ>MT_!IN3S M2FLK/1IC/)>\I5VROE),K*2A[-5+&0LY!BP152436;2CM-Q[@A^[$G8TO@.* M_'G,>88C`<=LY>*"]9:*=+"0&2)0NY7BEC_;DW$$%6B0KI]=>T!R?F_ROP#@ M.>Y3RVG@I[.-IK-6DJ261%,Q?:\P%6#).X?4CVZ=VWRBY!.<-P"SZ MQ5$ZM8K%".\^;-(24D#GCW06Z_U*I/Q.$:\2>G,T86!59+P-_F)E\NY>X".\ M!X='ROF$''L@;$-*5;!+HON'AKS3+^H%>[1@'4>A.G?3HL^4?D"7@W`+/+,4 M*MC(P/458W?V-]Q:@@?]#!O:LK,NA]0->VO27L6Z\IK7R)WG(<92XT0EQ*Z*6=G'6CTO\TB=L6JR"3`&L.,5I_%W\JEM6!!]2/7H,R'.OE'*_(F>XAPT<:@QV$%'5\@ M;?EE-RMY_;X'"Z(0R^@.FWU[].O*=LMURY"<@<4L<36VS3%ZC@LPSF8(TF*T MQ+:E7;3*6--\=-Y%)X_9K%4%N7MV(X^&\-Q7#L=R#D MTN7:;*Q3-%-4CA:I7>.1XQ#,7.^2;5`\B(T92-U*[ST)2_(/R#F_D#*\6X=# M@5K82:!)J]Z6PEZTDL49&?QO\ M9P\YHY"Y:LFJ4`KT0=`+60='EBK$D'L8XGW::$,\??OH7_RY\Q6/C;)8O'TJ M8N^36UDB`Q-/%1R103VP`P(*RSILW!@RQRC;VW+?!NX0=MT'359)RUN;K'K/J=+I=3I=+J=+I=3I=+K\W&ETN MUZ+;*]1*-`R%GM]KE&T+7H"*2!9_*R;LWBBV;D,8B9?0!,8YS%33(43G,4I1 M$.W&4RF/PN.FRV5F2#&UXR\DCG144>I/^@&I)T`!)Z_.!A,)E>1Y:O@L'!)9 MR]J58XHD&K.['0`?ZDZ`#4D@`GIM7?BOOV9V:5J6CYQ)4&7A?8-(JW&3@*[" M)I.6Z;I!PULLI+-Z_*-U$%`$#M'*X=^Y?VP$O0[BN?\`$,[1CR.$NICJOX^G?HMS?Q7SWC63EQ/(\?)0MP[=YL/'%&`P#`K,[B M%QH?5';\/7MU:S8N`E8HG%[%MMSK=ZMK^CZ*":UCRBINX%^]8M#1;R1EUJ>1 MG+*SED-2G+8C.3(5J90RBONID*F4>]?<:^7K^6Y[E.+9K$V,;A:7:*W*LBJQ MWJJ";<@2/S@EXB6TT&TDL1U:_,?@/%8/XPPW,^.YVIEN29#O-1@:-G4;&>3P M!9#)*:[*(I@$UW-N4!0>J`T0ATKY2@5(=,2W*O)&!0AB""J,VQ!9,?(`[*)" M(`8OXE$?7MU:7*2&XMDMI!__`#K!_P`#"^A_QZI7@L;ISG#;P1IEJH[CZB>/ M7KL^TN1N%;LD=;JUMHUV]>CN-?KU0'EW^FL7?&]1 MH52BH!_7DUEK/)1!$FS:1>S!4'J,>9D@`)$6C"F$QC^@A[WM@``3L#B+>5U8 M^O6#::Z#I+8U_N]E_P#/U4_C+3K8_P"AORZ2^O6_7J/ZV]4,TBG;-B_(ZQ\D MLCSQ3:Z?JE#J-*US-(:>@Z]H,/+9^ZF3U.\T9>TO(RNSS52*G%F4A%K/&:HF M(DND6&Z7L-!!8$,$8 M0A6\DD:/(S,="J1:*!KJ=>H#Y"L?(GR?\7.EV MQXW2*:_L:S1])22+-(R-:;/A/YG[G3`Q2]S"`"_X%\S\I7E\/\OS=IN,M'96 M42$LAW5IEC!55+'64IIH.QT)T&O45\H?]>>%-P*Q_`>.4DYBLM-H3$`D@V7* M[3%6=PHTA$NNI[C4#4D=`6M80FKRYY(:)I7!2V#6^48J^N.^SFB:EI&(* M@CG4BQ:@<:R:>BG7;K^&K1C)#;<6Y3<@].B.*&LZ)3-DSWC>UK8TJ=R=LI77 MN>5&T,[#`33>T:!`F!Y'NK$DW*9L*Z!C(*"4YB^!C0,\/%N4<`PV!L\AQU+) MXRYDC+YX[9\BV)HFCD0Q5Y.S",MHVUM&&H!U`**MCFO#/E'D')ZG%,MD<-F< M?AUA^VDHJ86J5YEEBD$]J+W(TP0%-RDHVA(T)&^3]5V+&2M)CLREJH@IHQCDF6ZR3>8B+66*6H([$4VFL;>_<`*; MPE&*Y*\EKKIG`*X%>K M>/QA`?+N`CZ=2U3ECV.#X/%X/F%;"FKCI(;-9UMZM(UFP^NL5:5#NB=!^KJ# MR'!XJWR1R+,\DX#0&R;1>-EQ=72W+_'*UGM'L=+;(N^.M89*146TM@/("XI*+7J9DI:56;(KI M@DD](0X".I7'\/9KY%S^?YAS.[F<*V2=\?#4K35@&Q,*^-%GW16`39D>>=D5AM$@ M!]WI:#AS6=4SO'&^1:RT>KRF.V";S>GW)X[9N_U'S"`7(&<7'NUN$@PC8H5V48SAXUC%Q"`MV$?&QC$A&[1ND!CG']HZBJASG,8QA'HPX?P[` M<$P:<>XW$T6-1V?1F9V9W.K,S,223V'X`````=5[\@?(7*/DWDDO*N6SB;*R M(B>U%C140:*BH@``'<_B6))))/28264:K).FZIVKANH1P@Z04,@NW62,"B2Z M*Z8E4162.4#%,40,4P=P'OT3LJR*8W`9&&A![@@^H(^H/U'0;%)+'(KQ,PE4 M@J02"".X(T]"#Z=;NM@YKUQYQOXJ<7W>00B>X17Z*W6W:1)M*_-GA%I!R1^W M?IA)12\HKH5YK#IB_E5UA`6XR)RB=58`,3Y,QOQ?>AY+RCGL62E_BSP9&&&L MID0.%C92IVN$%>"4/'$H_5XP=%7L?N[*?,^+GXCPKXOGQ$'\UCM8JQ/;<12& M,O(K*XW1ES:LPM%+.S$%?*PU9QJMRY*3D9)8YI!\[>^)S>)7*ZBJ9/4?1)(Q MO:2*']Q2@`=<_$_0/R'75V3];?F?\^CB@Z9*Y]'71E%-O<6N$",*60)*2D$>X1(H\*`@`"?U#Q#L;Q\BF3*&TU^AZQ!TZ(LGHSW;[(VHBLJA' M2Z3%[(L;&_*9VL#!F8BCR+=H>\BO)^0N!4;F\_<1$#@(BF/8OCML&[Z=(#7M MU]53J3RA\C:A3G[MH_>5W4:U&K/&(F%JY,G+L3E52*?ZTQ,10/(AOJ(;N4?4 M.D3NB+?BO7H&C:=;RNF/6WJJ^_T_XR->E/5H2PPXVY(IDJP M.^^.O)(C%V0LQ5P"-Q(T&A&G;JK.?X?QI7R-:[E()[&7H1.(KMF-/'+:ABD5 M8UD"*&0D':H.I+`@]^N.UV*/Q;3,@@W-FT!S5)^!V!Y)MGSF^:8_D)5@.;C$ MF<@DA9IP&T8BY="AY>+=$5C^H&4[#[CZ4W*,%DK204UR$,U,*5%>JJHWW._3 M4Q1ZL0N[U9MH^@[8Y7(U^%\FQ%&6UD&Q4]?(,X9K5QG=?L_'NT$TNB`OMUT1 M=S?5N^*N6ULY_2Q)`!]- M=>FF8YK#D.28RE@Y[:(U?(/(K06(%;QU@T9)GBC5BCD,`"2#WTTZ%L0LM3EL MYJ$^RO&US&AN\?;3C]2UR.TK5MQ.KT9)[+2!OS2U2I*B@/E3JMQ*;VP/XBA^ M!>I#E5'(U\W9IRU<7'AER1C7Q+2$HC$Y5%_:)G`V@!M>^FH?Z]1?",EB;?'* ME^&]FIN0MAQ*YG?(F$RFL&D?]]16)W$LFATUT*?3H!R+0_NLKQCBL\O^MV2_ M6BKP-HUN#T)U?754?Y[^32?F^S$5T9B@V++-+B_CRL#0"PJ&67`JB8LS'.67 MY'AOMZ^=L9FGCH,17GDBJ25Q7$JV/-^S%I68G885D\GW`T`753Y0`8#B7(?N MK?&:O'LAEK.?M58IK\5MK30/4^W'W$P-M0/(MAHA$:K:EGT93"6(/]YV*QQ& MC/7M/N36)KG&J*B+WJU7"1BT%]'+:4SFE*09L^.1=1>HY65[84"I"!EI5S%E M#N'F'4/Q'C5*SA%BR59I+N"I+MPB6<_@>I_GG,< MC3Y&\^'N)%C>-11VKT&^,&YYQ[ZVC$$FO1\EM0O=IWJCN-PZ(M6N-<=[!F[* M9NFBLJ)/X]=;1&)YB_T4$YF4+:,Z1B9=T&9H.)%R@2'EE@;G7_\`'[+CX]S" M'3/CV,NQ\:O2U:M)LM#DH(F-I:VJ)XK)=!]T0H.]%W!?=[>_8=27*\QCI>7X MV"Y=R*8*QA[,Z"DUO21_/4$',` MD$U&B].]:XW7Q3:W!W:EY1[+L]'I3!&2E"W5-.RF=,DG[E!N+D`\&ZGBF M'MB7H.RE0_QVW$$, M'',AE/%#)=@M4PAD19``XM;QM<%2&VKJ"#W4'Z=/^1FQ:Y=BL+Y[$6/M4L@9 M!%*\19HVI>-M\95PR;WT(8=F8>AZ"N1\CK%^> MQ[=JXSBEV1TS=LUYXR,HS=3$DNHHFZ!8IRJ"0?H^GJ5SN7*8'&21U,_:9`IIUI MF5E,NCJTCL2'W`@[?T]NE[G-ROVJM\TRXUVL$"F\J%]T;1+E&K(%NSPJPS%;->M6A8 M'PH[54FEFD0$>30$!$)V%G9G#!=I'^.YC/,X.MV>].+FR4 MD#N&RJ\M"?GX\H9I;D(\C@(\#O$8U1VH0'*1D_4@]BL]B\KEJ=;DU6A%BQ85 MI)8H!"VW0@(_V^W6$MM\FB-*$!V,#ZE6.!)Z5MR=@"W82(>8$;T>5"_&6QV"%8Q22+8\5,4V M@#QJ[>;7PL$8HNO_`)*B3;ZOIT(IDN$'%RJN6Y.;@FBC:IY[YR"63',R+X-/ MN%,BB1]/_#DN3O)_0N']7XY.>B9]QK=5&CUASRAA,_MT>6& MC(V0@E,PMTI]\:(4>;K7S6K!*0(W=-E9)HH)VBB:XD*I]:P<$X'AODFQS7@> M:I7.;K9GE&+>Q"V]V63[J%?&3.DFTR&,LK")QI(I34K\+6/DWY+Y!\/U?COY M.X[D,S1G6%ED*AJBZ%_3ZK=* MRR3O$/SCX5:#QL-\QWLIGX\59XIRBGC)6"BU+1FV*3]946,E$U[;PS:>I`&I%1\A_Z M_8G#<7ES=+G'#+^9A4LU.#)UB[*">T+M(HDDT[["J:]PI9M`;*?TQ\HXI9SK M#J>YB7WC/./+'4`3S*F3-\J>CP\)*F=)NI25N#J'4G,TAY0\4F"+-N_DCNB& M.K^Y(H!1`'^=N0_(.:X\M3XVJ9V**&SK:F2O-6=TT(5(0X2RZ[^[M'&$("^X MC7JR?^LO%/BCCG*FO?+U_C4\]FII3KR6H+<<;E@7>PT9EIQOL&V-99MX+-[% M8`]5PYW_`*7OOZA]S=XVFFA45-`SX71!5^$T-:"MZ\%E4AF4BLDY;PIY`!^, M0I"-_#U;E!`4NBGXW_YZ+X'$?)B3DAC+FG;MK*B1_<4_P`O M]LW_`#V__$/^KUS#3]`_(==IY/ZC?F>O3VC_`.G_`-=O_P!WK+K#K(Q*,T,B MU"!^?]W\C?#^SN#A)>?@;S^*+%8'7E[??OX?X>_?TZ1T^OIU[^71]D:3L-ES M?YGG\L-$K7R_DKD,Z^0$XV]_Y`**BN9Q[G?S\NYQ-W[^O6+_`*#^77J^O6^S MIAUMZ6&K5]C8X>K-9"PQE;3CM/S"P(.I11%-&1?5Z\0DNQKS45W+8II.Q.FA M6;8I1,/@R-.K%8L15ECR=*4,Y`#M%9CD6)=2OOE91&@&I+,-`3VZ\S]?8O=7 MS:R*V&-8R$#6-*CV=:741+*3[>>6HIGLA'I&O45A=X9IZS-*`=D9C$^U6.F@,F\[=2/T-H#WT5_'P33J=@J`QCYQ'E6>-SG)7FO=TY$I%`*CZF$@?5T[P>1GIXV[7AK2S+*]4 MEU!*Q^.;P=C-SY"O7R,>9>\TABD,>BN9MSQD! M`^X'50-`0WJ/IU$\-:X2.8,TC1;6`5R02 MI4G:?0]<$EGU?>9;AU4B="K,??ZA%5!QBUZ(Y9JIST]4ZBD5XK#1Z4FDXL=8 MMU1;NTY1FU74]V'*J9"M'GZD5E3DZI2QDU+?/NOO#R/<,YAV M\DHEC"QCQJR8-%S^;>,0;E'T[".[)WN7Y"6*?#092M@U@C2LD8GV^&,;%8%` MJNSLKO(ZC1I6<]-L-C.`XJ":MR&UA+G)6LRR7)937WFQ*WD9"LC,\:QHR1Q1 ML=5A6,=?3CV<0=4L='>PVD5RTP43FN@0^;Q4<[:.WCK++->:?9JFZ8.T)-V6 M6@J7&-&T0D\0(+=9NHU'R*8>Q\.2YNUD*-N*U1GKVY+U=[+L"%%N*":*8,"H MV23L6F*,=RL)!H0.VSA_'*.)R-&:EDJUJC%C;<=-$969J,UJO-`RL';R15D5 M*ZR*"K(8CJ">YEH5>L[O4*!9Z39:*QL\/2M'A0K%Q+(K+S$)/3&3)'+)39Y$$;J_P"T MT2*QT*CRKJ02NN+L=3NDQ,TB?;7>B5K=*Q&6L6L2+5BRK+#817,; MI($:+<5,H\;+^Y&3Z%`RM'@:T,E!O;C*1[ M>9DY"?LLK(OT(HCU\(((-$2-T2(D%4YUM.1R%-L(<9QZK8CQ(L))//*0[R2[ M9%A1BBK'$BJ92B>YG)=BQV@*XQ.*R"5'&?NFE,V^,N;?C55C#>+PJJP[MRC] MURRR'14"$87$ %1I!__]D_ ` end